Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade-Reference-Cited by-同舟云学术

Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade

Published:2022-07 Issue: Volume:181 Page:106264
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Alausa Abdullahi,Lawal Khadijat Ayodeji,Babatunde Oluwakemi Arinola,Obiwulu E.N.O.,Oladokun Olajumoke Christianah,Fadahunsi Olumide Samuel,Celestine Ugwu Obiora,Moses Emmanuel Ugbede,Akaniro Ifunanya Rejoice,Adegbola Peter Ifeoluwa

Funder

University of Missouri

Publisher

Elsevier BV

Subject

Pharmacology

Reference150 articles.

1. JP. The future of immune checkpoint therapy;Sharma;Science,2015

2. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential;Sharma;Cell,2015

3. The CD47-SIRPa signaling axis as an innate immune checkpoint in cancer;Matlung;Immunol. Rev.,2017

4. Trends in the incidence of pancreatic adenocarcinoma in all 50united states examined through an age period Cohort analysis;Wilson da Costa;JNCI Cancer Spectr.,2020

5. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS;Hodi;Nat. Clin. Pract. Oncol.,2008

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment;Journal of Pharmaceutical Analysis;2024-09

2. CD47-mediated immune evasion in early-stage lung cancer progression;Biochemical and Biophysical Research Communications;2024-08

3. Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma;Cancers;2024-04-11

4. Excavation of gene markers associated with pancreatic ductal adenocarcinoma based on interrelationships of gene expression;IET Systems Biology;2024-03-26

5. GATA6 Reduces Pancreatic Cancer Cell Stemness by Modulating Wnt/β-Catenin Signaling;J BIOL REG HOMEOS AG;2024